It’s officially Fall, y’all.
Fingers crossed that this will be a September to remember for patients with neurodegenerative diseases (NDs). Same for October, November, December etc.
Recent preclinical data from the laboratory of Queensland University of Technology (QUT) Associate Professor, Dr. Richard Gordon, demonstrate that RRx-001 significantly modifies the clinical trajectory of several NDs, which is awesome or, rather, autumn (in honor of September). 🍂 The hope is that the disease modifying effects of RRx-001 will also extend to the prevention or reduction of cognitive decline.
EpicentRx and Dr. Gordon have been awarded several prestigious grants from the Michael J Fox Foundation, the US Department of Defense (DoD) and others to investigate the activity of lead EpicentRx small molecule, RRx-001 (nibrozetone), in several ND indications including Parkinson’s, Amyotrophic Lateral Sclerosis (ALS)/Motor Neurone Disease (MND), and central nervous system (CNS) toxic exposures.
Separately, Dr. Gordon submitted an abstract on the anti-Parkinsonian activity of RRx-001 that was accepted for a poster presentation, so we’ll plan to be at MDS in not-so-chilly Philly. We’re super excited to hear Dr. Gordon’s talk assuming he decides to make the 23-hour flight from Down Under — and it looks like he will. Dr. Gordon is a super trooper, but 20+-hour trips are “planely” too long. ✈️
In any case, for us, and probably for Dr. Gordon too, this is sure to be a September to remember.